Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

95.30 +1.00 (+1.06%)
Streaming Delayed Price Updated: 3:46 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
From Incyte
Via Business Wire
News headline image
Incyte (INCY) Q4 Earnings: What To Expect
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be announcing earnings results this Tuesday before market open. Here’s what to look for. 
Via StockStory
Topics World Trade
Value Investing Opportunity: Incyte Corp. (NASDAQ:INCY) Presents a Compelling Case ↗
Via Chartmill
News headline image
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
From Incyte
Via Business Wire
News headline image
2 Profitable Stocks Worth Investigating and 1 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Incyte Corp. (NASDAQ:INCY) Emerges as a Compelling Value Stock with Strong Fundamentals ↗
Via Chartmill
Incyte Corp (NASDAQ:INCY) Shows High-Growth Momentum and Strong Technical Trend ↗
Via Chartmill
Which S&P500 stocks are moving on Friday? ↗
Via Chartmill
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
2 Value Stocks Worth Investigating and 1 That Underwhelm
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful... 
Via StockStory
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
3 Value Stocks Worth Investigating
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Topics Credit Cards
News headline image
2 Mid-Cap Stocks with Exciting Potential and 1 We Question
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
Why Incyte (INCY) Stock Is Trading Up Today
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.2% in the afternoon session after TD Cowen maintained a 'Buy' rating on the stock and increased its price target. The... 
Via StockStory
Topics Artificial Intelligence
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Rule Breaker Investing Market Cap Game Show: Is Your Favorite Stock in the Spotlight? ↗
It's time once again for the Market Cap Game Show Holiday Edition, where intuition meets valuation and everyday life meets market caps. 
Via The Motley Fool
News headline image
2 Cash-Heavy Stocks Worth Investigating and 1 Facing Challenges
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
These S&P500 stocks are moving in today's session ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Wednesday. ↗
Via Chartmill
News headline image
Incyte (INCY) Stock Is Up, What You Need To Know
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.7% in the morning session after the company announced positive top-line results from a late-stage study of its lymphoma... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
News headline image
2 Safe-and-Steady Stocks Worth Your Attention and 1 Facing Challenges
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Monday's session: top gainers and losers in the S&P500 index ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Top S&P500 movers in Monday's session ↗
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Monday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session. 
Via Chartmill
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Announces Change to its Board of Directors
From Incyte
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.